FINWIRES · TerminalLIVE
FINWIRES

$KVUE

16 stories mentioning KVUEUpdated 25d ago

Every FINWIRES story that references KVUE, newest first.

What's the latest news on KVUE?

Wire

Kenvue to Sell Feminine Care Business in Brazil to Essity

Kenvue (KVUE) has struck a deal to sell its feminine care business in Brazil to Essity for $284 million on a cash and debt-free basis, the latter said Wednesday.The hygiene and health company said the acquisition, including Carefree and Sempre Livre brands, would strengthen its position as a market leader in feminine care in Latin America.The transaction is expected to close in Q2 of 2027, the firm said.Price: $19.06, Change: $+0.26, Percent Change: +1.38%

$KVUE
Stocks Mostly Up Pre-Bell as Investors Weigh Potential Iran-Oman Hormuz Deal, Await More Earnings
US Markets

Stocks Mostly Up Pre-Bell as Investors Weigh Potential Iran-Oman Hormuz Deal, Await More Earnings

US equity markets were mostly pointing higher before the opening bell Thursday as investors assess prospects for a potential deal between Iran and Oman over the Strait of Hormuz and await the latest batch of corporate earnings.The S&P 500 edged up 0.1% and the Dow Jones Industrial Average rose 0.2% in premarket activity, while the Nasdaq declined 0.3%. The Nasdaq and S&P 500 finished the previous trading session lower, while the Dow logged a fresh closing high for a third straight day.Iranian Deputy Foreign Minister Kazem Gharibabadi reportedly said Thursday that an "understanding" between Iran and Oman regarding the Strait of Hormuz is close to being finalized, CNBC reported. Gharibabadi noted that the path of understanding is between the two countries and no negotiations have taken place with the US during this period.Earlier in the week, President Donald Trump reportedly said an agreement to reopen the strait, the world's most important chokepoint for crude flows, was imminent.West Texas Intermediate crude oil dipped 0.1% to $75.16 a barrel before the open, while Brent was slightly in the green at $79.47.ConocoPhillips (COP), Parker Hannifin (PH), Datadog (DDOG), Warner Bros. Discovery (WBD), Becton Dickinson (BDX), Keurig Dr Pepper (KDP), Kenvue (KVUE), Restaurant Brands International (QSR), Fiserv (FISV), Ralph Lauren (RL), Fox (FOX, FOXA), US Foods (USFD) and Unity Software (U) report their latest financial results before the bell, among others.Cloudflare (NET), Monster Beverage (MNST) and Airbnb (ABNB) are scheduled to post their earnings after the markets close.Shares of Applovin (APP) dropped 16% pre-bell after the mobile technology provider's second-quarter revenue fell short of market estimates. DoorDash (DASH) gained 2.4% as the company delivered a second-quarter revenue beat amid order momentum. SanDisk (SNDK) fell 8.9% following its latest quarterly results.Employers in the US announced 33,429 layoffs in July, down 27% from the month prior and 46% year over year, according to Challenger, Gray & Christmas' latest report. The weekly jobless claims bulletin is out at 8:30 am ET.On Wednesday, ADP (ADP) data showed that private-sector employment in the US increased less than expected last month as gains were concentrated in services. The government's nonfarm payrolls report for July is due on Friday.Treasury yields were trending higher in premarket action, with the two-year rate inclining 2.1 basis points to 4.2% and the 10-year rate adding 1 basis point to 4.63%.Federal Reserve Bank of St. Louis President Alberto Musalem is slated to speak at 5:30 pm.Gold traded up 0.5% at $4,328 per troy ounce, while bitcoin decreased 0.4% to $64,606.

Dow JonesNasdaq CompositeS&P 500$ABNB$ADP$APP$BDX$COP$DASH$DDOG$FISV$FOX$FOXA$KDP$KVUE$MNST$NET$PH$QSR$RL$SNDK$U$USFD$WBD
Wire

Kimberly-Clark Delivers Solid Q2 Despite Sales Headwinds, RBC Says

Kimberly-Clark's (KMB) Q2 earnings beat showed the company can deliver steady profit growth despite cost swings and operational disruptions, RBC Capital Markets said Wednesday in a report.Adjusted earnings were $2.12 per share, above the $2 consensus estimate, as cost savings, supply-chain productivity and a $45 million tariff refund offset a revenue miss. Sales were pressured by US retailer destocking, a fire at a Los Angeles distribution center and disruption in China's diaper market following social media claims about product quality, the report said.Profit and margins would have been roughly in line with expectations even without the tariff refund, supporting the view that Kimberly-Clark's organizational redesign and improved cost management are strengthening its earnings performance, the report said.Management lowered its 2026 outlook, partly reflecting the China disruption, which is expected to reduce H2 operating profit by $70 million, the report said. RBC cut its full-year earnings estimate to $7.43 a share from $7.65.RBC remained positive on Kimberly-Clark's planned acquisition of Kenvue (KVUE), expected to close in Q4. Management said integration planning is ahead of expectations and that the estimated $1.9 billion in cost savings is achievable with potential upside, according to the report.RBC maintained its outperform rating on Kimberly-Clark stock and its $162 price target.Price: $111.54, Change: $-0.03, Percent Change: -0.03%

$KMB$KVUE
Wire

Kenvue Increases Quarterly Dividend to $0.21 from $0.2075 a Share; Payable Aug. 26 to Holders of Record Aug. 12

Kenvue Increases Quarterly Dividend to $0.21 from $0.2075 a Share; Payable Aug. 26 to Holders of Record Aug. 12

$KVUE
Wire

Kenvue's Tylenol With Naproxen Combination Tablet Gets FDA Approval for Pain Relief

Kenvue's (KVUE) Kenvue Brands unit received approval for its Tylenol with Naproxen combination tablet to provide up to 12 hours of pain relief in adults and children 12 years and older, the US Food and Drug Administration said Friday.The nonprescription combination product is indicated for temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor arthritis pain, the FDA said.The agency said the approval was supported by data showing the effectiveness and safety of the combination drug.Kenvue shares were up about 1.1% in Friday trading.Price: $19.11, Change: $+0.21, Percent Change: +1.08%

$KVUE
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.5%.The iShares Biotechnology ETF (IBB) fell 1.4%.In corporate news, Conmed (CNMD) shares jumped 9% after Bloomberg Law reported that the company is exploring options including a potential sale amid takeover interest from private equity firms.A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder. Kenvue shares were down 1.5%.Humana (HUM) shares gained 4.1% after Wells Fargo upgraded the company's stock to overweight from equal-weight and increased the price target to $502 From $227.Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a note. Hemab shares rose 3.3%, and Incyte was down 1.5%.

$CNMD$COAG$HUM$INCY$KVUE
Sectors

Sector Update: Healthcare Stocks Higher Monday Afternoon

Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index rising 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.4%.The iShares Biotechnology ETF (IBB) fell 1.6%.In corporate news, a federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder. Kenvue shares were down 1.4%.Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a note. Hemab shares gained 6.5%, and Incyte was down 1.8%.Niagen Bioscience (NAGE) has received rare pediatric disease designation from the US Food and Drug Administration for NB4168 in treating ataxia telangiectasia, a multisystem disorder, the company said Monday. Its shares rose 1.6%.

$COAG$INCY$KVUE$NAGE
Wire

Update: Kenvue Must Face Claims Linking Tylenol to Autism, Appeals Court Says

(Updates with Kenvue's response to a request for comment in the last paragraph.)A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder.The two cases impacted by the appeals court ruling were remanded for further proceedings."The procedural ruling today does not change the fact that credible, independent science shows no proven link between taking acetaminophen and autism or attention deficit hyperactivity disorder," Kenvue said in a statement to. "Science matters, and we stand with the many public health and medical professionals who have reviewed the science on this topic and agree. We now have another opportunity to show that the plaintiffs' experts' opinions are unreliable and should not be allowed in this case. We stand behind the safety of our product and will continue to defend these cases."Price: $19.18, Change: $-0.31, Percent Change: -1.57%

$KVUE
Wire

Top Midday Stories: Trump Says US to Be Guardian of Hormuz Strait; Meta to Invest Over $50 Billion in Louisiana Data Center Expansion

All three major US stock indexes were down in late-morning trading Monday, as the US and Iran exchanged airstrikes over the weekend.President Donald Trump said Monday on Truth Social that the US will act as "THE GUARDIAN OF THE HORMUZ STRAIT" and will receive reimbursement for all incurred costs "at the rate of 20% on all cargo shipped." Trump said the strait is open and will remain so for all non-Iranian vessels.In company news, Meta Platforms (META) said Monday it plans to invest over $50 billion in its Richland Parish, Louisiana, infrastructure project to expand its computing capacity to 5 gigawatts. The tech giant will finance seven new natural gas-generating plants and three grid-scale batteries to completely cover its power requirements. Meta shares were down 1% around midday.Funds managed by Blackstone (BX) Credit & Finance, in partnership with Apollo Global Management (APO) and KKR-managed (KKR) insurance vehicles will invest $5.34 billion in Williams' (WMB) five Power Innovation projects in exchange for a 49% noncontrolling equity interest in the projects, Williams said Monday. Blackstone shares were down 0.8%, and Williams shares were down 0.1%. Apollo and KKR shares were down 0.8% and 0.3%, respectively.Taiwan Semiconductor Manufacturing (TSM) said Monday its net revenue for June totaled about 442.68 billion New Taiwan dollars ($13.79 billion), up 6.2% from the previous month and up 67.9% from a year earlier. Its shares were down 1.2%.First Hawaiian (FHB) said Monday it has signed a definitive agreement to acquire TriCo Bancshares (TCBK) in an all-stock deal. Under the deal terms, TriCo shareholders will receive 2.095 First Hawaiian shares for each TriCo share, valued at $63.12 per share based on First Hawaiian's July 10 closing price. First Hawaiian shares were down 4.6%, while TriCo shares were up 10.5%.Ferguson Enterprises (FERG) said Monday it has entered into a definitive agreement to acquire FWI Holdings, or FloWorks, in a deal with an enterprise value of about $1.6 billion. The deal is expected to close in Q3, subject to regulatory approvals and closing conditions. Ferguson shares were up 2.1%.Roughly a dozen states are set to file a lawsuit Monday in federal court in an effort to block Paramount Skydance's (PSKY) acquisition of Warner Bros. Discovery (WBD), Bloomberg reported, citing a person familiar with the matter. Paramount and Warner Bros. shares were up 2.7% and 0.5%, respectively.A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder attention-deficit/hyperactivity disorder. Kenvue shares were down 1.6%.Price: $662.82, Change: $-6.39, Percent Change: -0.95%

$APO$BX$KKR$KVUE$META$PSKY$TSM$WBD$WMB
Wire

Kenvue Must Face Claims Linking Tylenol to Autism, Appeals Court Says

A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder.The two cases impacted by the appeals court ruling were remanded for further proceedings.Kenvue didn't immediately reply to a request for comment from.Price: $19.30, Change: $-0.18, Percent Change: -0.95%

$KVUE
Wire

Kenvue Must Face Claims Linking Tylenol to Autism, Appeals Court Says

Kenvue Must Face Claims Linking Tylenol to Autism, Appeals Court Says

$KVUE
Insider Trading

Kenvue Insider Sold Shares Worth $679,691, According to a Recent SEC Filing

Matthew Orlando, General Counsel, on May 08, 2026, sold 38,491 shares in Kenvue (KVUE) for $679,691.SEC Filing:https://www.sec.gov/Archives/edgar/data/1944048/000194404826000100/xslF345X05/wk-form4_1778617643.xml

$KVUE
Research

Research Alert: CFRA Keeps Hold View On Shares Of Kenvue Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target price at $19, which is 16.5x our 2027 EPS view of $1.15, a discount to the trading multiple of 18.1x since going public in 2023. We think this multiple is justified given the litigation overhang and limited visibility into KVUE's standalone performance (the company is no longer providing forward-looking guidance and hosting an analyst call) due to the pending acquisition by Kimberly-Clark (KMB), expected to close during Q2 2026. We increase our 2026 EPS estimate to $1.15 from $1.10 following this morning's Q1 earnings release. We maintain our 2027 EPS estimate at $1.15. Kenvue delivered a solid first quarter that demonstrated continued operational momentum. Net sales increased to $3,909M (+4.5% Y/Y) with organic growth of 0.7%. The performance suggests management's operational initiatives are gaining traction as the company approaches the transaction close. The transaction received shareholder approval in January 2026, and regulatory approvals are progressing.

$KVUE
Research

Research Alert: CFRA Keeps Hold View On Shares Of Kenvue Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target price at $19, which is 16.5x our 2027 EPS view of $1.15, a discount to the trading multiple of 18.1x since going public in 2023. We think this multiple is justified given the litigation overhang and limited visibility into KVUE's standalone performance (the company is no longer providing forward-looking guidance and hosting an analyst call) due to the pending acquisition by Kimberly-Clark (KMB), expected to close during 2H 2026. We increase our 2026 EPS estimate to $1.15 from $1.10 following this morning's Q1 earnings release. We maintain our 2027 EPS estimate at $1.15. Kenvue delivered a solid first quarter that demonstrated continued operational momentum. Net sales increased to $3,909M (+4.5% Y/Y) with organic growth of 0.7%. The performance suggests management's operational initiatives are gaining traction as the company approaches the transaction close. The transaction received shareholder approval in January 2026, and regulatory approvals are progressing.

$KVUE
Research

Research Alert: Kenvue Reports Solid Q1 Performance Amidst Pending Kimberly-clark Acquisition

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Kenvue (KVUE) delivered solid Q1 results with net sales of $3,909M (+4.5% Y/Y) and organic growth of 0.7%, marking the second consecutive quarter of growth. Diluted EPS surged to $0.25 vs. $0.17 (+47%) while adjusted EPS reached $0.32 vs $0.24 (+33%), due to significant margin expansion with gross margin improving 90bps to 58.9% and operating margin jumping 470bps to 19.6%. The strong performance demonstrates operational momentum ahead of the pending Kimberly-Clark acquisition, with supply chain optimization and cost management initiatives driving results. . Segment performance was mixed, with Skin Health & Beauty leading at +8.4% growth while Self Care faced headwinds from weak cold/flu seasons, posting an organic sales decline of 2.3%. Since management is no longer providing forward guidance and hosting an analyst call due to the transaction expected to close during 2H 2026, we have limited visibility into KVUE's performance expectations at this point.

$KVUE
Wire

Kimberly-Clark Shows Steady Performance Amid Volatile Macros, RBC Says

Kimberly-Clark (KMB) showed a steady Q1 performance amid volatile macros and Kenvue (KVUE) acquisition, RBC Capital Markets said in a note on Wednesday.The report said the company topped organic sales and earnings per share expectations in the quarter."Share performance in the US and internationally signals strong fundamentals and that ongoing M&A activity (Suzano JV and KVUE acquisition) is not impacting execution," the note said.Guidance was largely reiterated, and the firm pointed to potential inflation in H2 on rising oil prices, the note said, adding that new guidance will be issued if the Kenvue deal closes in H2."We continue to see more upside than downside to KMB," it said. RBC kept its outperform rating with a $162 price target.Price: $96.96, Change: $-1.48, Percent Change: -1.50%

$KMB$KVUE

Track with the FINWIRES app suite

FolioX
FolioX
Track KVUE in your portfolio
WheelAI
WheelAI
Analyze KVUE options with the wheel strategy
StockInsider
StockInsider
See market sentiment on KVUE